Morimatsu (China) Investments, a wholly-owned subsidiary of Morimatsu International Holdings Co. Ltd., has been actively engaged in investment holding business within the People's Republic of China. The company recently participated in a significant transaction involving the Target Company, a non-wholly owned subsidiary. The Target Company, known for serving industries such as pharmaceuticals, biopharmaceuticals, and fast-moving consumer goods, is set to receive an additional registered capital of RMB12,946,412. This capital infusion, amounting to RMB330,000,000, was agreed upon through a transaction with investors, highlighting Morimatsu (China) Investments' ongoing commitment to supporting its subsidiaries in expanding their industry presence and capabilities.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。